Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05968651 · ClinicalTrials.gov registry record · Phase 2
Social Safety Learning in the Brain Oxytocin System
A Phase 2 study, sponsored by University of Washington.
- Completed
- Registry status
- Phase 2
- Development phase
- 121
- Enrollment target
NCT05968651 is a Phase 2 study that has completed, run by University of Washington. The registered enrollment target is 121 participants.
The verdict
NCT05968651, a Phase 2 study, has completed, sponsored by University of Washington.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 121 participants
- Enrollment target
Study Summary
The investigators are conducting this research study to examine whether oxytocin enhances social safety learning (learning safety through the experience of another individual) in people with social anxiety disorder (SAD) compared to healthy volunteers. Oxytocin is a hormone that can also act as a chemical messenger in the brain. Oxytocin plays a role in a number of functions, including responding to fear and social interactions. In this study, the investigators would like to compare the effects of oxytocin and placebo nasal sprays in adults with SAD and healthy adults. This research study will compare an oxytocin nasal spray to a placebo nasal spray. About 120 people will take part in this research study, all at the University of Washington (UW).
Interventions
- DRUG Oxytocin nasal spray or placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 121 participants |
| Start Date | 2023-06-26 |
| Est. Completion | 2024-09-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05968651
The ClinicalTrials.gov registry entry for NCT05968651 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 121 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Washington, which has 1,048 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Oxytocin nasal spray or placebo is the first listed.
NCT05968651 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05968651 about?
NCT05968651 is a clinical study titled "Social Safety Learning in the Brain Oxytocin System". The investigators are conducting this research study to examine whether oxytocin enhances social safety learning (learning safety through the experience of another individual) in people with social anxiety disorder (SAD) compared to healthy volunteers. Oxytocin is a hormone that can also act as a ch...
What is the current status of trial NCT05968651?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 121 participants. The study started on 2023-06-26. Estimated completion is 2024-09-30.
What interventions are being tested in trial NCT05968651?
The interventions under investigation include: Oxytocin nasal spray or placebo (DRUG).
Who is sponsoring clinical trial NCT05968651?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.